Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Ryan C, Lynch"'
Autor:
Marek Trněný, Abraham Avigdor, Matthew S. McKinney, Shankara Paneesha, Björn E. Wahlin, John S. Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch
Publikováno v:
EClinicalMedicine, Vol 63, Iss , Pp 102130- (2023)
Summary: Background: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) asse
Externí odkaz:
https://doaj.org/article/c66821b07c654aec8c095879560486da
Autor:
Ryan C. Lynch, Stefan Alig, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei Shustov, Brian Till, Vikram M. Raghunathan, Yolanda Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jackie Vandermeer, Ashley Gaston, Heather Rasmussen, Avanti Gulhane, Delphine L. Chen, Paul Martin, Edmond Marzbani, Jenna Voutsinas, Ash A. Alizadeh, Ajay K. Gopal
Publikováno v:
HemaSphere, Vol 6, Pp 26-27 (2022)
Externí odkaz:
https://doaj.org/article/1dca62dfced740de83e0d17bd541a259
Autor:
Ryan C. Lynch, Ranjana H. Advani
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 3, Pp 813-818 (2017)
The B-cell receptor signaling pathway is important in the lymphomagenesis of many lymphomas, including marginal zone lymphoma (MZL). Herein we describe a case of extranodal MZL refractory to multiple lines of therapy. The presence of an IgM paraprote
Externí odkaz:
https://doaj.org/article/93269368626542cfb42366a4c866c129
Autor:
Ryan C. Lynch, Stefan K. Alig, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei Shustov, Brian G. Till, Vikram Raghunathan, Yolanda D. Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather A. Rasmussen, Avanti Gulhane, Delphine Chen, Eric Wayne Dean, Paul S. Martin, Edmond A Marzbani, Jenna M. Voutsinas, Ash A. Alizadeh, Ajay K. Gopal
Publikováno v:
Blood. 140:6547-6549
Autor:
Hun Ju Lee, Jeremy S. Abramson, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Domingo Domenech Eva, Brian T. Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Giuseppe Rossi, Uwe H Hahn, Henry Miles Prince, Linda Ho, Wenchuan Guo, Christopher A. Yasenchak, David J. Straus
Publikováno v:
Blood. 140:9399-9401
Autor:
Lorena Panaite, Qian 'Vicky' Wu, Jenna Voutsinas, Erin Mullane, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Stephen D. Smith, Ajay K. Gopal, Christina Poh, Lorenzo Iovino, Cameron J. Turtle, David G. Maloney, Brian G. Till, Jordan Gauthier, Mazyar Shadman
Publikováno v:
Leukemia & Lymphoma. 63:2918-2922
Cytopenias are important but less studied adverse events following chimeric antigen receptor-engineered T cell (CAR-T) therapy. In our analysis of patients with large cell lymphoma who received axicabtagene ciloleucel (axi-cel), we sought to determin
Autor:
Michael A. Thompson, Jeremy L. Warner, Leyre Zubiri, Trisha M. Wise-Draper, Pallawi Torka, Christopher Su, Aditi Shastri, Sumit A. Shah, Andrew Schmidt, Rachel Rosovski, Pedram Razavi, Matthew M. Puc, Andrew J. Portuguese, Hyma V. Polimera, Adam J. Olszewski, Taylor K. Nonato, Amanda Nizam, Gayathri Nagaraj, Rana R. McKay, Gary H. Lyman, Xuanyi Li, Eric Lau, Tahir Latif, Chris Labaki, Daniel H. Kwon, Nicole M. Kuderer, Vadim S. Koshkin, Elizabeth J. Klein, Anup Kasi, Monika Joshi, Nathalie A. Johnson, Clara Hwang, Daniel Hausrath, Shilpa Gupta, Christopher R. Friese, Devendra KC, Jacob C. Cogan, Cecilia A. Castellano, Mehmet Asim Bilen, Stephanie Berg, Babar Bashir, Ziad Bakouny, Joy Awosika, Sarit E. Assouline, Melissa Accordino, Alicia Beeghly-Fadiel, Matthias Weiss, Catherine Stratton, Keith E. Stockerl-Goldstein, R. Alejandro Sica, Dimpy P. Shah, Daniel P. Mundt, Sanjay Mishra, Ruben A. Mesa, Shailesh Advani, Yu Shyr, Chih-Yuan Hsu, Ryan C. Lynch, Divaya Bhutani, Samuel M. Rubinstein
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a8d5a0ca3f513af54198bd82bbe3af3
https://doi.org/10.1158/2643-3230.c.6550638
https://doi.org/10.1158/2643-3230.c.6550638
Autor:
Michael A. Thompson, Jeremy L. Warner, Leyre Zubiri, Trisha M. Wise-Draper, Pallawi Torka, Christopher Su, Aditi Shastri, Sumit A. Shah, Andrew Schmidt, Rachel Rosovski, Pedram Razavi, Matthew M. Puc, Andrew J. Portuguese, Hyma V. Polimera, Adam J. Olszewski, Taylor K. Nonato, Amanda Nizam, Gayathri Nagaraj, Rana R. McKay, Gary H. Lyman, Xuanyi Li, Eric Lau, Tahir Latif, Chris Labaki, Daniel H. Kwon, Nicole M. Kuderer, Vadim S. Koshkin, Elizabeth J. Klein, Anup Kasi, Monika Joshi, Nathalie A. Johnson, Clara Hwang, Daniel Hausrath, Shilpa Gupta, Christopher R. Friese, Devendra KC, Jacob C. Cogan, Cecilia A. Castellano, Mehmet Asim Bilen, Stephanie Berg, Babar Bashir, Ziad Bakouny, Joy Awosika, Sarit E. Assouline, Melissa Accordino, Alicia Beeghly-Fadiel, Matthias Weiss, Catherine Stratton, Keith E. Stockerl-Goldstein, R. Alejandro Sica, Dimpy P. Shah, Daniel P. Mundt, Sanjay Mishra, Ruben A. Mesa, Shailesh Advani, Yu Shyr, Chih-Yuan Hsu, Ryan C. Lynch, Divaya Bhutani, Samuel M. Rubinstein
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44698d30596b4e81fbac34bfa3f7919a
https://doi.org/10.1158/2643-3230.22544427.v1
https://doi.org/10.1158/2643-3230.22544427.v1
Autor:
Ryan C Lynch, Chaitra S Ujjani, Christina Poh, Edus H Warren, Stephen D Smith, Mazyar Shadman, Brian G. Till, Vikram Raghunathan, Stefan Alig, Ash A Alizadeh, Avanti Gulhane, Delphine Chen, Yolanda Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather Rasmussen, Paul Martin, Edmond Marzbani, Jenna M Voutsinas, Ajay K Gopal
Publikováno v:
Blood.
Concurrent administration pembrolizumab with chemotherapy in untreated classical Hodgkin lymphoma (CHL) has not previously been studied. To investigate this combination, we conducted a single arm study of concurrent pembrolizumab with AVD (APVD) for
Autor:
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Weina Chen, Bouthaina Dabaja, Megan E. Daly, Leo I. Gordon, Neil Hansen, Alex F. Herrera, Ephraim P. Hochberg, Patrick B. Johnston, Mark S. Kaminski, Christopher R. Kelsey, Vaishalee P. Kenkre, Nadia Khan, Ryan C. Lynch, Kami Maddocks, Jonathan McConathy, Monika Metzger, David Morgan, Carolyn Mulroney, Sheeja T. Pullarkat, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Pallawi Torka, Jane N. Winter, Joachim Yahalom, Joanna C. Yang, Jennifer L. Burns, Mallory Campbell, Hema Sundar
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:322-334
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that